兰州生物技术开发有限公司

Lanzhou Biotechnology Development Co., Ltd., a subsidiary of China National Biotec Group (CNBG) under Sinopharm, is a prominent Chinese biopharmaceutical company specializing in the research and production of botulinum toxin products. The company is most famous for developing and manufacturing Hengli (BTXA), which was the first Botulinum Toxin Type A to be approved in China and remains the only domestically produced brand in the market. Its products are utilized extensively in both therapeutic fields, such as neurology and ophthalmology, and the rapidly growing medical aesthetics sector for wrinkle reduction. Lanzhou Biotech operates advanced GMP-certified manufacturing facilities and exports its biological products to over 30 countries and regions worldwide.